For localized information and support, would you like to switch to your country-specific website for {0}?
Clinically actionable respiratory testing across the continuum of care
Roche PCR respiratory solutions deliver timely, high-quality insights for confident decision-making in every setting and situation.
In the face of complex and ever-evolving respiratory challenges, you need diagnostic solutions that offer both precision and flexibility.
It’s now possible to offer polymerase chain reaction (PCR) - or lab quality respiratory testing - for patients in all settings. This can include urgent care clinics, doctor’s offices, emergency departments, hospital labs and more. And it’s possible to partner with just one manufacturer to ensure the availability of high-quality testing in each of those settings and for the unique situations and preferences of your providers and their patients.
Roche PCR respiratory solutions: Transforming what’s possible in respiratory testing
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Roche has developed a comprehensive range of respiratory tests, technologies and assays for primary, secondary, and community care settings. We are helping customers to transform what’s possible with respiratory testing.
Show video transcript
Quick, targeted point-of-care testing
cobas® liat system
- Provides results in 20 minutes or less supporting real-time clinical decision-making
- Intuitive, easy to use interface
- Frontline multiplex assays
Comprehensive and fast results
cobas® eplex system .
- Urgent results for high-risk patients in ~1.5 hours
- Broad pathogen detection panels (viral and bacterial)
- Modular & scalable
- Easy-to-use workflow
Flexible and efficient testing
cobas® 5800/6800/8800 systems
- Flexible ordering/ reporting
- Scalable solutions for labs of all sizes
- Minimal and intuitive technician interactions
The Roche respiratory testing continuum
Outlining possibilities to enhance care across all pathways with Roche respiratory solutions
Introduction to cobas® Respiratory flex
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Featured products
IVD
For in vitro diagnostic use.
cobas® Respiratory flex
cobas® Respiratory flex utilizes TAGS technology for fast PCR results for up to 12 viral respiratory infections testing available on all cobas® x800 systems.
IVD
For in vitro diagnostic use.
cobas® Influenza A/B & RSV
Diagnose and differentiate influenza A/B & RSV for effective clinical management and infection control with the POC multiplex PCR test for use on the cobas® liat system.
IVD
For in vitro diagnostic use.
cobas® eplex respiratory pathogen panel 3
The cobas® eplex respiratory pathogen panel 3 (RP3 panel) is a multiplexed nucleic acid in vitro diagnostic test intended for use on the cobas® eplex system for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) in transport media obtained from individuals suspected of respiratory tract infections.The following virus types, subtypes, and bacteria are identified using the cobas® eplex RP3 panel: adenovirus, enterovirus/rhinovirus, human bocavirus, human coronavirus 229E, human coronavirus HKU1, human coronavirus NL63, human coronavirus OC43, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human metapneumovirus, human parainfluenza virus 1, human parainfluenza virus 2, human parainfluenza virus 3, human parainfluenza virus 4, influenza A virus, influenza A virus H1, influenza A virus H1-2009, influenza A virus H3, influenza B virus, respiratory syncytial virus (RSV) A, respiratory syncytial virus (RSV) B, Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae.The detection and identification of specific viral and bacterial nucleic acids from individuals exhibiting signs and symptoms of respiratory tract infection aids in the diagnosis of respiratory infection when used in conjunction with other clinical and epidemiological information.Results are for the detection of nucleic acid from respiratory pathogens that are detectable in NPS specimens during infection. Positive results are indicative of active infection with the identified respiratory pathogen; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Negative results do not preclude respiratory infection due to other non-panel organisms and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Positive results do not rule out co-infection with other organisms; the organism(s) detected by the cobas® eplex RP3 panel may not be the definite cause of disease. The use of additional laboratory testing (e.g., bacterial and viral culture, immunofluorescence and radiography) and clinical presentation must be taken into consideration in the final diagnosis of respiratory tract infection.